DePuy Synthes entered into an exclusive agreement with Prosidyan for U.S. promotion of FIBERGRAFT® ultra-porous synthetic bone graft in spinal fusion. This complements DePuy’s spinal biomaterials portfolio of cellular allograft, demineralized bone matrix and synthetics. DePuy Synthes will commence promotion within 2Q18.
To date, FIBERGRAFT products have been used in >10,000 procedures in the U.S.; the first FDA 510(k) clearance occurred in 2014 for a morsellized format, followed by putty in 2015 and matrix (morsels plus collagen) in 2017.
DePuy Synthes entered into an exclusive agreement with Prosidyan for U.S. promotion of FIBERGRAFT® ultra-porous synthetic bone graft in spinal fusion. This complements DePuy's spinal biomaterials portfolio of cellular allograft, demineralized bone matrix and synthetics. DePuy Synthes will commence promotion within 2Q18.
To...
DePuy Synthes entered into an exclusive agreement with Prosidyan for U.S. promotion of FIBERGRAFT® ultra-porous synthetic bone graft in spinal fusion. This complements DePuy’s spinal biomaterials portfolio of cellular allograft, demineralized bone matrix and synthetics. DePuy Synthes will commence promotion within 2Q18.
To date, FIBERGRAFT products have been used in >10,000 procedures in the U.S.; the first FDA 510(k) clearance occurred in 2014 for a morsellized format, followed by putty in 2015 and matrix (morsels plus collagen) in 2017.
Copy to clipboard 
